Characterisation of monoclonal antibodies to the TNF and TNF receptor families

被引:13
作者
Ch'en, PFT
Xu, XG
Liu, XS
Liu, Y
Song, CJ
Screaton, GR
Jin, BQ [1 ]
Xu, XN
机构
[1] Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China
[2] John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England
[3] Univ London Imperial Coll Sci & Technol, Hammersmith Hosp, London W12 0NN, England
关键词
DcR; decoy receptor; DR; death receptor; TRAIL; TNF related apoptosis inducing ligand; APRIL; a proliferation inducing ligand; BAFF; B cell activating factor of the TNF family; BAFF-R; BAFF receptor; BCMA; B cell maturation antigen; TACI; transmembrane activator and CAM L integrator;
D O I
10.1016/j.cellimm.2005.08.010
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Tumour necrosis factor (TNF) family ligands and their corresponding receptors play important roles in the immune system and are involved in immune regulation such as lymphoid development, cell proliferation, differentiation, activation and death. Antibodies against these ligands and receptors together with Fc-fusion proteins, have been particularly useful as immunological tools in addressing the underlying involvement of these proteins in these contexts and furthermore, have given us hope in using them as potential therapeutic agents. Over last few years, there have been many additions to these ever-growing TNF family ligands and their receptors. Here, we have generated and characterised a set of monoclonal antibodies, together with mAbs from the HLDA workshop, against DcR1, DcR2, DR4, DR5, TRAIL, APRIL, BAFF, BAFF-R, BCMA, and TACI, which may be useful in phenotypic and functional studies of the role of TNF and TNF receptor family in immune function and regulation in relation to health and disease. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:78 / 85
页数:8
相关论文
共 57 条
[1]   Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[2]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[3]   BAFF selectively enhances the survival of plasmablasts generated from human memory B cells [J].
Avery, DT ;
Kalled, SL ;
Ellyard, JI ;
Ambrose, C ;
Bixler, SA ;
Thien, M ;
Brink, R ;
Mackay, F ;
Hodgkin, PD ;
Tangye, SG .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (02) :286-297
[4]   A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis [J].
Boumpas, DT ;
Furie, R ;
Manzi, S ;
Illei, GG ;
Wallace, DJ ;
Balow, JE ;
Vaishnaw, A .
ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :719-727
[5]  
Brown SJ, 2005, CURR OPIN DRUG DISC, V8, P160
[6]   Death receptors couple to both cell proliferation and apoptosis [J].
Budd, RC .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (04) :437-441
[7]  
Cheema GS, 2001, ARTHRITIS RHEUM-US, V44, P1313, DOI 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO
[8]  
2-S
[9]   Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays [J].
De Vos, J ;
Thykjær, T ;
Tarte, K ;
Ensslen, M ;
Raynaud, P ;
Requirand, G ;
Pellet, F ;
Pantesco, V ;
Rème, T ;
Jourdan, M ;
Rossi, JF ;
Orntoft, T ;
Klein, B .
ONCOGENE, 2002, 21 (44) :6848-6857
[10]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820